Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
Chi-Heng Wu(National Taiwan University), Weiyun Z. Ai(City College of San Francisco), Brian Hinds(University of California San Diego), Ryan M. Gill(University of California, San Francisco), Laura Pincus(University of California, San Francisco), Frank McCormick(Frederick National Laboratory for Cancer Research), Linlin Wang(University of California, San Francisco), Kwun Wah Wen(University of California, San Francisco), Chen‐Yen Yang(University of California, San Francisco), Mark M. Moasser(University of California, San Francisco)
Cited by 33
Related Papers
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
|Nature|2007|991
Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target
|Cancer Cell|2013|571
In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study
|Journal of Clinical Oncology|2010|487